Patients with atypical haemolytic uraemic syndrome (aHUS) for whom eculizumab treatment is delayed beyond 7 days are significantly more likely to require dialysis than those who start treatment earlier.

Delaying eculizumab initiation beyond 7 days also leads to significantly increased healthcare costs compared with earlier initiation.